Please assess the completion status of the following clinical trial:

Trial Title: Maintenance Treatment of Iron Deficiency in IBD Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~Non-anaemic patients treated in the FERGI-CORRECTION study (Hb ≥12 g/dL female, ≥13 g/dL male), independent of ferritin value.~Females of child-bearing potential must have a negative urine pregnancy test at screening and be practising an acceptable method of birth control during the study and for up to 1 month after the last dose of study medication.~Exclusion Criteria:~Chronic alcohol abuse (alcohol consumption \>20 g/day).~Presence of portal hypertension with oesophageal varices. History of erythropoietin, intravenous or oral iron therapy, or blood transfusion in 12 weeks prior to screening.~Known hypersensitivity to FERINJECT®.~History of acquired iron overload.~Myelodysplastic syndrome.~Pregnancy or lactation.~Known active infection, clinically significant overt bleeding, active malignancy. Known chronic renal failure.~Surgery with relevant blood loss (defined as Hb drop \<2 g/dL) in the 3 months prior to screening or planned surgery within the following 3 months.~Chronic liver disease or increase of liver enzymes (alanine aminotransferase (\[ALT\], aspartate aminotransferase \[AST\]) \>3 times the upper limit of normal range.~Known human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.~Inability to fully comprehend and/or perform study procedures in the investigator's opinion.~Participation in any other interventional study (except correction study) within 1 month prior to screening.~Body weight \<35 kg.~Significant cardiovascular disease, including myocardial infarction within 12 months prior to study inclusion, congestive heart failure NYHA (New York Heart Association) grade III or IV, or poorly controlled hypertension according to the judgment of the investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ferinject (Type: EXPERIMENTAL): Intravenous infusion of iron
- Placebo (Type: PLACEBO_COMPARATOR): NaCL 0,9%

Based on this trial design, predict the completion outcome and termination type (if applicable).